MX2021003558A - Sistemas de suministro polimerico de accion prolongada. - Google Patents

Sistemas de suministro polimerico de accion prolongada.

Info

Publication number
MX2021003558A
MX2021003558A MX2021003558A MX2021003558A MX2021003558A MX 2021003558 A MX2021003558 A MX 2021003558A MX 2021003558 A MX2021003558 A MX 2021003558A MX 2021003558 A MX2021003558 A MX 2021003558A MX 2021003558 A MX2021003558 A MX 2021003558A
Authority
MX
Mexico
Prior art keywords
delivery
delivery systems
compositions
delivery vehicle
polar aprotic
Prior art date
Application number
MX2021003558A
Other languages
English (en)
Inventor
Thomas B Ottoboni
Lee Ann Lynn Girotti
Original Assignee
Heron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heron Therapeutics Inc filed Critical Heron Therapeutics Inc
Publication of MX2021003558A publication Critical patent/MX2021003558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Se describen composiciones que comprenden un vehículo de suministro o sistema de suministro y un agente activo dispersado dentro del vehículo o sistema de suministro, en donde el vehículo o sistema de suministro contiene un polímero de poliortoéster y un solvente aprótico polar. También se describen sistemas de suministro de baja viscosidad para la administración de agentes activos. Los sistemas de suministro de baja viscosidad tienen un polímero de poliortoéster, un solvente aprótico polar y un solvente que contiene un agente reductor de viscosidad triglicérido. Las composiciones descritas incluyen un anestésico local de tipo amida o anilida de la clasificación "caína", y un fármaco anti-inflamatorio no esteroideo (NSAID, por sus siglas en inglés), junto con métodos relacionados, por ejemplo, para el tratamiento de dolor post-operativo o para tratamiento profiláctico del dolor. Las composiciones son apropiadas para suministrarse por medio de, por ejemplo, aplicación e instilación directa, inyección intradérmica, inyección subcutánea, y bloqueo de nervio (perineural).
MX2021003558A 2014-04-21 2016-10-19 Sistemas de suministro polimerico de accion prolongada. MX2021003558A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982314P 2014-04-21 2014-04-21
US201461996788P 2014-05-14 2014-05-14
US201562131797P 2015-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
MX2021003558A true MX2021003558A (es) 2021-05-27

Family

ID=53002830

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013719A MX2016013719A (es) 2014-04-21 2015-04-20 Sistemas de suministro polimerico de accion prolongada.
MX2021003558A MX2021003558A (es) 2014-04-21 2016-10-19 Sistemas de suministro polimerico de accion prolongada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016013719A MX2016013719A (es) 2014-04-21 2015-04-20 Sistemas de suministro polimerico de accion prolongada.

Country Status (21)

Country Link
US (4) US10213510B2 (es)
EP (2) EP3936115A1 (es)
JP (5) JP6702882B2 (es)
KR (2) KR102450730B1 (es)
CN (4) CN114886899B (es)
AU (3) AU2015249949B2 (es)
BR (1) BR112016024665B1 (es)
CA (2) CA2946281C (es)
CY (1) CY1124575T1 (es)
DK (1) DK3134068T3 (es)
ES (1) ES2893376T3 (es)
HR (1) HRP20211612T1 (es)
HU (1) HUE055973T2 (es)
LT (1) LT3134068T (es)
MX (2) MX2016013719A (es)
PL (1) PL3134068T3 (es)
PT (1) PT3134068T (es)
RS (1) RS62435B1 (es)
SI (1) SI3134068T1 (es)
TW (1) TWI675661B (es)
WO (1) WO2015164272A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
JP6363115B2 (ja) 2013-02-28 2018-07-25 ミラ ファーマ コーポレイション 注射可能局所麻酔半固体製剤およびその組成物
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
PT3134068T (pt) 2014-04-21 2021-10-18 Heron Therapeutics Inc Sistemas de libertação poliméricos de longa duração
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
JP6723162B2 (ja) 2014-04-21 2020-07-15 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ポリオルトエステルおよび有機酸添加剤の組成物
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
FI20155779A (fi) 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
US11964046B2 (en) * 2016-05-17 2024-04-23 Alberta Veterinary Laboratories Ltd Topical composition for the control of pain in animals
RU2749398C2 (ru) * 2016-12-26 2021-06-09 Целликс Био Прайвет Лимитед Композиции и способы лечения хронической боли
EP3691618A1 (en) 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
JP7046396B2 (ja) * 2017-12-06 2022-04-04 湖州惠中濟世生物科技有限公司 注射可能な長時間作用性局所麻酔薬半固形製剤
CN108158998B (zh) * 2017-12-28 2021-01-26 广州玻思韬控释药业有限公司 一种布比卡因多囊脂质体制备装置
KR20210060492A (ko) * 2018-09-07 2021-05-26 헤론 테라퓨틱스 인코포레이티드 수술 후 통증 치료
CN110935024B (zh) * 2018-09-21 2023-08-08 合肥合源药业有限公司 长效组合物
WO2020086737A1 (en) * 2018-10-23 2020-04-30 Baudax Bio, Inc. Methods of administering intravenous meloxicam pre-operatively and in combination with other drugs
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
CN113116823B (zh) * 2019-12-30 2024-02-20 江苏恒瑞医药股份有限公司 一种脂质体及其制备方法
WO2021141959A1 (en) * 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
CN115666621A (zh) * 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
WO2021143745A1 (zh) 2020-01-14 2021-07-22 中国科学院上海药物研究所 一种长效罗哌卡因药物组合物及其制备方法和用途
CN113980254A (zh) * 2020-07-10 2022-01-28 南京泛太化工医药研究所 一种具有酸敏感降解、温敏性质的系列聚合物及其载药组合物
EP4274573A1 (en) 2021-01-11 2023-11-15 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
CN115068414B (zh) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
BR112023018896A2 (pt) 2021-03-19 2023-10-10 Pacira Pharmaceuticals Inc Tratamento da dor em pacientes pediátricos por administração de composições anestésicas lipossômicas de liberação prolongada
WO2023105227A1 (en) * 2021-12-08 2023-06-15 Nanexa Ab New injectable combination formulation
KR20230115591A (ko) * 2022-01-27 2023-08-03 주식회사 티온랩테라퓨틱스 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법
WO2024052766A1 (en) * 2022-09-05 2024-03-14 Welfare Concepts Limited Cytotoxic agent for chemical disbudding and method
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4549010A (en) 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
US4780319A (en) 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
US4957998A (en) 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
EP0869986B1 (en) * 1996-01-05 2000-11-02 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
IT1283252B1 (it) 1996-03-15 1998-04-16 Pulitzer Italiana Soluzioni di piroxicam iniettabili per via parenterale
JP4467789B2 (ja) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
US7991679B2 (en) 1999-12-22 2011-08-02 Bgc Partners, Inc. Systems and methods for providing a trading interface
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
EP1424957A2 (en) 2001-09-14 2004-06-09 Francis J. Martin Microfabricated nanopore device for sustained release of therapeutic agent
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
CN1822816A (zh) * 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
US7666914B2 (en) 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
EP1781596B1 (en) * 2004-07-12 2008-10-08 Xenoport, Inc. Amino acid derived prodrugs of propofol compositions and uses thereof
PT1809329E (pt) 2004-09-17 2012-03-29 Durect Corp Composição anestésica local prolongada contendo aibs
ES2528720T3 (es) 2004-11-10 2015-02-12 Tolmar Therapeutics, Inc. Sistema de suministro de polímero estabilizado
EP2361630A1 (en) 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
US20070264338A1 (en) 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264339A1 (en) 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
EP2044142A2 (en) * 2006-06-29 2009-04-08 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US20090124952A1 (en) 2007-11-09 2009-05-14 Berman David A Herpes Treatment and Dressing
US20100015049A1 (en) 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
WO2010019953A1 (en) 2008-08-15 2010-02-18 Arcion Therapeutics, Inc. High concentration local anesthetic formulations for treating non-neuropathic pain
US20100203102A1 (en) * 2009-02-10 2010-08-12 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent
US8603051B2 (en) 2009-02-17 2013-12-10 Kuvio, Inc. Implantable drug delivery devices
WO2010138918A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
US20110033545A1 (en) 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2012151442A1 (en) 2011-05-03 2012-11-08 Cummins Inc. Control techniques for an scr aftertreatment system
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
CA2906666C (en) 2013-03-15 2019-12-24 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
JP6723162B2 (ja) 2014-04-21 2020-07-15 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ポリオルトエステルおよび有機酸添加剤の組成物
PT3134068T (pt) 2014-04-21 2021-10-18 Heron Therapeutics Inc Sistemas de libertação poliméricos de longa duração
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems

Also Published As

Publication number Publication date
LT3134068T (lt) 2021-10-11
AU2023202876A1 (en) 2023-05-25
EP3134068A2 (en) 2017-03-01
HUE055973T2 (hu) 2022-01-28
CA3174824A1 (en) 2015-10-29
AU2015249949B2 (en) 2020-07-30
CN106535886A (zh) 2017-03-22
TWI675661B (zh) 2019-11-01
WO2015164272A2 (en) 2015-10-29
CN114886899B (zh) 2024-02-13
US20210220474A1 (en) 2021-07-22
JP2017513871A (ja) 2017-06-01
SI3134068T1 (sl) 2021-11-30
HRP20211612T1 (hr) 2022-02-04
CA2946281A1 (en) 2015-10-29
ES2893376T3 (es) 2022-02-08
EP3134068B1 (en) 2021-07-21
WO2015164272A3 (en) 2015-12-17
KR20170005017A (ko) 2017-01-11
BR112016024665B1 (pt) 2023-04-11
AU2020207850B2 (en) 2023-02-23
US11413350B2 (en) 2022-08-16
CN113908284A (zh) 2022-01-11
US20170281778A1 (en) 2017-10-05
CY1124575T1 (el) 2022-07-22
PT3134068T (pt) 2021-10-18
EP3936115A1 (en) 2022-01-12
CA2946281C (en) 2022-12-13
PL3134068T3 (pl) 2021-12-20
DK3134068T3 (da) 2021-10-04
CN115025099A (zh) 2022-09-09
US20160375140A1 (en) 2016-12-29
AU2020207850A1 (en) 2020-08-13
US10898575B2 (en) 2021-01-26
JP6702882B2 (ja) 2020-06-03
US10213510B2 (en) 2019-02-26
JP2020114887A (ja) 2020-07-30
US9694079B2 (en) 2017-07-04
CN113908284B (zh) 2023-08-04
RS62435B1 (sr) 2021-11-30
JP2021138773A (ja) 2021-09-16
US20150297729A1 (en) 2015-10-22
BR112016024665A2 (pt) 2018-06-19
JP2019526601A (ja) 2019-09-19
AU2015249949A1 (en) 2016-11-03
MX2016013719A (es) 2017-07-11
CN114886899A (zh) 2022-08-12
TW201605445A (zh) 2016-02-16
KR20220138419A (ko) 2022-10-12
JP2022017553A (ja) 2022-01-25
JP7181248B2 (ja) 2022-11-30
KR102450730B1 (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2021003558A (es) Sistemas de suministro polimerico de accion prolongada.
WO2015038811A3 (en) Liquid protein formulations containing ionic liquids
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
EP4144390A3 (en) Vial transfer and injection apparatus and method
MX2018006139A (es) Envase farmaceutico para formulaciones oftalmicas.
MX2022012914A (es) Dispositivos y metodos para administracion y mezcla de farmaco, y entrenamiento de tecnicas apropiadas para ello.
WO2015095624A3 (en) Drug mixing and delivery system and method
IN2013DN02524A (es)
EP3506817A4 (en) METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
EP4173615A3 (en) Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
MX2019013327A (es) Formulación para administración ocular de fármacos.
WO2018141941A3 (en) Methods and systems for improving stability of pre-vapor formulations of e-vaping devices
BR112017002356A2 (pt) composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
EP4299019A3 (en) Systems for delivery of gel embolics
WO2014117010A3 (en) Composition for ophthalmic administration
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
BR112017012289A2 (pt) agente para injeção hipodérmica
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof